Themis Medicare Limited submitted its Investor Presentation for Q1 FY27 (quarter ended 30th June, 2026) to BSE and NSE in compliance with Regulation 30 of SEBI LODR Regulations, 2015. The presentation provides a business overview and financial results update.

Financial Highlights (Consolidated, Q1 FY27)

Revenue Performance:

  • Net Revenue: ₹86.96 crore, representing a 10.9% decline year-over-year (YoY) from ₹97.58 crore in Q1 FY26
  • Sequentially, revenue increased from ₹76.53 crore in Q4 FY26

Expenditure Breakdown:

  • Cost of Material Consumed: ₹17.63 crore (vs ₹12.43 crore in Q1 FY26)
  • Purchase of Stock-in-Trade: ₹49.81 crore (vs ₹21.68 crore in Q1 FY26)
  • Changes in Inventory: (₹9.46) crore (vs ₹18.29 crore in Q1 FY26)
  • Employee Expenses: ₹22.18 crore (vs ₹24.85 crore in Q1 FY26)
  • Other Expenses: ₹59.21 crore (vs ₹30.41 crore in Q1 FY26)
  • Total Expenditure: ₹139.38 crore, up 29.5% YoY from ₹107.66 crore

Profitability Metrics:

  • EBITDA: (₹52.42) crore, compared to (₹10.08) crore in Q1 FY26 - a 420% decline
  • EBITDA Margin: (60.28%), down 4,995 basis points from (10.33%) in Q1 FY26
  • Other Income: ₹0.99 crore (vs ₹1.18 crore in Q1 FY26)
  • Depreciation: ₹2.54 crore (vs ₹2.55 crore in Q1 FY26)
  • Interest/Finance Cost: ₹2.98 crore (vs ₹2.47 crore in Q1 FY26)
  • Share of P/L of Associates & JV: ₹2.59 crore (vs ₹(0.14) crore in Q1 FY26)
  • Profit Before Tax (PBT): ₹38.60 crore, a significant improvement from loss of ₹14.06 crore in Q1 FY26
  • Profit After Tax (PAT): ₹24.61 crore, compared to loss of ₹14.22 crore in Q1 FY26 - a 273.1% improvement
  • PAT Margin: 28.30%, improved by 4,287 basis points from (14.57%) in Q1 FY26
  • Basic EPS: ₹2.67, compared to (₹1.54) in Q1 FY26

Balance Sheet (as of 31st March 2026):

  • Total Assets: ₹597.91 crore (vs ₹588.03 crore as of 31st March 2025)
  • Non-Current Assets: ₹292.93 crore
  • Plant, Property & Equipment: ₹166.40 crore
  • Capital Work in Progress: ₹2.47 crore
  • Intangible Assets: ₹0.12 crore
  • Investments: ₹108.50 crore
  • Other Financial Assets: ₹1.55 crore
  • Other Non-Current Assets: ₹13.90 crore
  • Current Assets: ₹304.98 crore
  • Inventories: ₹81.09 crore
  • Trade Receivables: ₹178.12 crore
  • Cash & Cash Equivalents: ₹4.54 crore
  • Bank balances other than above: ₹4.61 crore
  • Other Financial Assets: ₹6.41 crore
  • Other Current Assets: ₹30.21 crore

Company Snapshot:

  • Market Capitalization: ₹1,084 crore (as of 30th June 2026)
  • EBITDA Margin (FY25-26): 0.11%
  • PAT (FY25-26): ₹1.14 crore
  • Debt to Equity Ratio: 0.25 (FY25-26)
  • Manufacturing Facilities: 3 facilities in India (1 Formulations, 2 APIs - Synthetic + Biotech)
  • Global Presence: Exports to 44+ countries
  • Employee Strength: 6 PhDs, 210 Masters, and 1,124 others

Management Commentary:

Dr. Sachin Patel, Managing Director & CEO, stated that the company navigated market headwinds in Q1 FY27. The improvement in bottom-line performance was predominantly contributed by one-off gains. The Critical Care business registered growth driven by focused brand promotion, while the API and institution business show promise with visibility of healthy recovery in FY27. The company continues to prioritize cash flow through faster collections, recovery of long-pending receivables, optimization of working capital, and overall cost efficiencies. R&D investments were around 8% of revenue.

Strategic Focus:

  • Enhance profitability and cash flow through improved clinic effectiveness, targeted doctor outreach, and operational efficiencies
  • Strengthen presence in Hospital and API businesses
  • Focus on achieving leadership position in India with corporate hospitals and nursing homes
  • Expand into new RoW markets in Phase I, with plans to enter regulated markets (EU, USA) in Phase II
  • Develop APIs for in-house consumption and commercial production
  • Vision to provide hospitals and health systems with 'The Best Experience Leader business model'

R&D Capabilities:

  • Continued investment in R&D with specific focus on both API and Formulations businesses
  • API Business: 5-8 products developed per year with documentation, 3-5 products in rolling work
  • Formulations Business: 20-24 products developed per year with documentation, 31 products in rolling work

Hospital Business Opportunity:

  • Growing market with high fragmentation in India compared to Western markets
  • Themis has strong foothold in Critical Care segment
  • High entry barriers due to need for large product portfolio and time to build relationships
  • Focus on leadership in Anesthesia and Critical Care segments